Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Visual outcomes after implantation of the PanOptix trifocal intraocular lens

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Multifocal IOLs

Venue: Poster Village: Pod 1

First Author: : J.Alio SPAIN

Co Author(s): :    A. Plaza-Puche   P. Yebana   J. Alio del Barrio   P. Amat   V. Ortuno   R. Fernandez Buenaga

Abstract Details

Purpose:

To evaluate visual and optical performance of eyes following lens extraction and trifocal lens (Acrysof IQ PanOptix, Alcon) implantation

Setting:

Vissum Corporation and Miguel Hernández University, Alicante, Spain

Methods:

50 eyes of 25 patients were enrolled in this study group. In all cases, the trifocal Acrysof IQ PanOptix IOL (Alcon) was implanted. The following visual and refractive parameters postoperatively were measured: distance (4m) near (40cm) and intermediate (80cm) visual acuities, contrast sensitivity, defocus curve, ocular aberrometry and quality of life questionnaire (NAV Q10). The Follow-up period was 1 and 3 months after surgery.

Results:

Uncorrected and corrected distance visual acuities improved significantly after surgery (p<0.01). Uncorrected near visual acuities were 0.17±0.12 and 0.19±0.17 at 1 month and 3 months after surgery, respectively. Uncorrected intermediate visual acuities were 0.11±0.16 and 0.10±0.14 at 1 month and 3 months postoperatively, respectively. At 3 months 87.5% of eyes have a spherical equivalent within ±0.50D and 98% within ±1.00D. Defocus curve showed a visual acuity of 0.20logMAR o higher for defocus levels between +0.50 and -3.00D. Mean contrast sensitivity was 1.59±0.18 Log units. 72.5% of patients are very satisfied with their near vision.

Conclusions:

The trifocal Acrysof IQ PanOptix IOL provides good far vision as well as adequate intermediate and near visual acuities with good contrast sensitivity outcomes and adequate rate of patient satisfaction.

Financial Disclosure:

NONE

Back to previous